Talent Investment Fund Seeks DKK 100 Mln for Startups in Denmark

Til Nasdaq Copenhagen A/S, Copenhagen, Denmark - The Danish Medicines Agency has approved Til Pharma's submission for the approval of a new generic product, Tilnis 0.5mg/ml, for the treatment of ADHD in children and adolescents. The agency has accepted Til Pharma's dossier for the product, which is expected to be launched in the second quarter of 2023. The approval follows Til Pharma's successful completion of a bioequivalence study and pharmacokinetic study in healthy adult subjects. The company expects to receive the final approval from the Danish Medicines Agency by the end of 2022.